Shares of PepGen, Inc. (NASDAQ:PEPG – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.80.
Several equities analysts recently issued reports on PEPG shares. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research report on Tuesday, April 21st. Wedbush decreased their price target on PepGen from $9.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Oppenheimer initiated coverage on PepGen in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, Guggenheim lifted their price target on PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th.
Check Out Our Latest Analysis on PepGen
Hedge Funds Weigh In On PepGen
PepGen Stock Performance
PEPG stock opened at $1.68 on Friday. PepGen has a 52 week low of $1.01 and a 52 week high of $7.80. The firm’s fifty day moving average is $3.25 and its 200 day moving average is $4.75. The firm has a market cap of $116.20 million, a P/E ratio of -0.70 and a beta of 2.01.
PepGen (NASDAQ:PEPG – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. As a group, analysts forecast that PepGen will post -1.22 EPS for the current year.
About PepGen
PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.
The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).
Featured Articles
- Five stocks we like better than PepGen
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.
